Renal amino acid transport in adults with oxidative phosphorylation diseases  by Shoffner, John M. et al.
Kidney international, Vol. 47 (1995), pp. 1101—1107
Renal amino acid transport in adults with oxidative
phosphorylation diseases
JOHN M. SHOFFNER, ALEXANDER S. VOLJAVEC, JOHN DIXON, ALLAN KAUFMAN, DOUGLAS C. WALLACE,
and WILLIAM E. MITCH
Department of Genetics and Molecular Medicine, Department of Neurology, and Department of Medicine (Renal Division), Emo,y University School of
Medicine, Atlanta Georgia, USA
Renal amino acid transport in adults with oxidative phosphorylation
diseases. The clinical manifestations of mitochondrial DNA (mtDNA)
mutations depend on a variety of factors including ratios of normal to
abnormal mtDNA and tissue-specific differences in ATP production by
oxidative phosphoiylation (OXPHOS). In order to investigate the effects
of OXPHOS defects on renal tubule function, we characterized sodium-
coupled transport processes in six individuals with OXPHOS diseases.
Pathogenic mtDNA mutations were identified in five of these individuals.
Sodium coupled transport processes were evaluated by determining
fractional excretions of amino acids, glucose, lactate, urate, and phosphate
in patients and controls. Four of the six individuals had high fractional
excretions of neutral amino acids, indicating abnormal renal tubule
reabsorbtion of these amino acids. Abnormalities in fractional excretions
of lactate, glucose, urate, and phosphate were less pronounced. These
results demonstrate that sodium-coupled transport processes in the kidney
are sensitive to OXPHOS impairment. When abnormalities in these
processes are encountered, an OXPHOS disease should be included in the
differential diagnosis.
Oxidative phosphorylation (OXPHOS) diseases are clinically
and genetically heterogeneous disorders characterized by varying
degrees of defective ATP production. Impaired ATP production
can be caused by mutations in OXPHOS genes coded by the
nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) [1].
OXPHOS is a complex series of five protein-lipid enzyme com-
plexes (Complexes Ito V) that are located in the inner membrane
of the mitochondria. Complexes I and II collect electrons gener-
ated during the catabolism of fats, proteins, and carbohydrates
and transfer them sequentially through Complex III, cytochrome
c, and Complex TV. Energy derived from electron transfer is used
by complexes I, III, and IV to translocate protons across the inner
mitochondrial membrane, producing an electrochemical gradient
that is used by Complex V to condense ADP and inorganic
phosphate into ATP.
The normal functioning of OXPHOS to produce ATP requires
the coordinate expression of both nDNA and mtDNA genes.
Pathogenic mtDNA mutations can be homoplasmic (that is, all
mtDNAs have the same sequence) or heteroplasmic (that is, two
or more mtDNAs with different sequences). Heteroplasmic
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mtDNA mutations undergo a random segregation of normal and
mutant mtDNAs during cytokinesis, a process referred to as
replicative segregation. This would account for much of the
genetic and phenotypic variability that occurs among tissues of an
affected individual. Thus, physiological expression of an OX-
PHOS defect depends on the distribution of mutant and normal
mtDNAs within cells of an organ, the tissue-specific dependence
on ATP for normal function, and the ability of each organ to
compensate for cellular dysfunction. As predicted from these
complex interactions, each organ reacts differently to OXPHOS
dysfunction. Hence, the clinical manifestations predictive of the
presence of an OXPHOS disease are still being defined.
The renal manifestations of OXPHOS diseases have been
described in children and include generalized aminoacidurias, the
Toni-Fanconi-Debré syndrome, isolated renal tubular acidosis,
Bartter's syndrome, and tubulointerstitial nephropathy [2—91. Of
these renal disorders, generalized aminoaciduria is the most
frequently encountered abnormality. Hence, ATP-dependent so-
dium-coupled transport in renal cells may be sensitive to alter-
ations in mitochondrial ATP production. To evaluate this hypoth-
esis, we investigated several sodium-coupled renal transport
processes in six adults with OXPHOS diseases but no evidence for
renal failure.
Methods
Patient selection
Six individuals with OXPHOS diseases who were identified in
the Emory Molecular Medicine Clinic volunteered for participa-
tion in the study. Informed consent was obtained from all patients
and control subjects and the study was approved by the Emory
University Human Investigations Committee.
Four individuals were from the maternal lineage of a previously
reported pedigree in which OXPHOS disease manifestations were
caused by an A to G mutation in the tRNA' gene at nucleotide
pair (np) 8344 of the mtDNA (MTTK*MERRF8344G) [10—121.
Patient 1 had myoclonic epilepsy and ragged-red fiber disease
(MERRF). She consistently demonstrated high plasma and urine
concentrations of lactate, pyruvate, alanine, glycine, and tricar-
boxylic acid cycle intermediates. The serum bicarbonate level was
normal. Two maternal lineage relatives had less severe manifes-
tations that included hearing loss and mitochondrial myopathy
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Table 1. PCR conditions and restriction endonucleases used for mutation screening
Mutation Primer sequence
Annealing
temperature
Restriction
endonuclease
MTFK*MERRF8356C 5'-CTATAGCACCCCCTCTACC-3'
3'-AT[T]TCACTTTACGGGGTFGATITA.-5'
51° Dral
M117LI *MELAS3271C 5'-CCCGATGGTGCAGCCGC-3'
3'-AAT[C]TCAGTCTCCAAGTFAAG-5'
53° DdeI
MT1TL1*MMC326OG 5'-GAGCCCGGTAATCGC[T]TA-3'
3'-GTGACGCTCGTCATCGG-5'
51° DdeI
MYLl *MM3250C 5'-GGmGTrAAGATGGCAGAG[GICCGG-3'
3'-ATGCGT[TFCCGGGGTFGCAC-5
59° NaeI
(patients 2 and 3). Patient 4 had myoclonic epilepsy, mitochon-
dna! myopathy and hearing loss. In these three members of the
pedigree, the blood and urine concentrations of these metabolites
were variable, ranging from markedly abnormal to normal. The
serum bicarbonate levels were normal in these individuals.
Patient 5 is a 43-year-old man with Kearns-Sayre syndrome
(KSS). He was the only affected individual within his pedigree.
Ptosis, chronic progressive external ophthalmoplegia, muscle
weakness, and fatigability developed between 11 and 25 years of
age. Other manifestations included difficulty swallowing due to
pharyngeal muscle weakness, diffuse muscle atrophy, chronic
diarrhea, cardiac arrhythmias, mitral valve prolapse, left anterior
fascicular block, and episodes of atrial fibrillation and supraven-
tricular tachycardia. Although cervical lipomas observed in some
MERRF patients were absent [13], several small lipomas were
located on his extremities. Lactate, pyruvate, and alanine concen-
trations in his blood and urine ranged from normal to abnormal.
Muscle biopsy revealed a mitochondrial myopathy with ragged-
red fibers, paracrystalline inclusions, and abnormalities of mito-
chondrial membrane structure. His serum bicarbonate level was
normal.
Patient 6 is a 55-year-old man with a mitochondrial myopathy.
No other symptomatic individuals were identified in his pedigree.
Exercise intolerance associated with nausea and vomiting began
between the ages of 20 and 25 years and could be induced by
moderate exertion. Muscle weakness progressed slowly over the
subsequent 30 years with the development of moderate proximal
weakness of his upper and lower extremities, mild facial muscle
weakness, and weakness of neck flexion and extension. Eye
movements, coordination, mental status, and sensory exam were
normal. Pathological analysis of a muscle biopsy revealed ragged-
red fibers, paracrystalline inclusions, abnormalities of mitochon-
drial membrane structure, and lipid vacuoles. The serum bicar-
bonate level was normal.
OXPHOS enzymology
Measurement of OXPHOS enzyme activities in skeletal muscle
mitochondria was performed as described [11, 14]. Abnormal
OXPHOS specific activity was defined as a value below the 5%
tolerance level of OXPHOS values measured in muscle biopsies
obtained from 39 normal subjects who had no prior history of
neuromuscular disease. The age range of the normal subjects was
18 to 78 years. Results were divided into two groups, individuals
<50 years and >50 years, to account for the effect of the
age-related decline in OXPHOS enzyme activity [15].
MtDNA analysis
The mtDNA from patient 6 was tested for the following point
mutations: MTATP6*NARP8993G and MTATP6*NARP8993C
[16, 17], MTTK*MERRF8356C [18, 19], MTTK*MERRF8344G
[12], MTFL1 *MELAS3271C [20], MTTL1 *MMC326OG [21],
MTTL1*MM3250C [22], and MTTL1*MELAS3243G [23].
Human Gene Map nomenclature is used to designate the
mtDNA point mutations [24]. DNA isolation, mtDNA South-
ern blot analysis, mtDNA amplification, and testing for
the MTATP6*NARP8993G, MTATP6*NARP8993C, MTFK*
MERRF8344G, and the MTTLI *MELAS3243G mutations
were performed as described (25). Testing for the MTFK*
MERRF8356C, Mliii*MELAS3271C, MTTL1 *MMC326OG
and MTTL1*MM3250C mutations was performed by amplifying
segments of mtDNA followed by restriction endonuclease diges-
tion for site recognition and separation of the fragments on either
8% polyacrylamide or 2.5% NuSieve/0.8% SeaKem agarose gels.
The sequences of the polymerase chain reaction (PCR) primers,
annealing temperature for the PCR, and the restriction endonu-
clease used for mutation detection are given in Table 1. These
mutations do not create naturally occurring restriction sites.
Therefore, the primers were designed to contain a novel nude-
otide (bracketed sequence) that is incorporated into the sequence
during amplification. Incorporation of this nucleotide into the
mtDNA fragment creates a restriction site only when the muta-
tion is present, thus simplifying sample screening and mutation
detection. mtDNA sequencing of the deletion breakpoint was
performed as described [12].
Analysis of proximal renal tubule function
Patients 1 to 4 were studied as inpatients in the Emory
University Clinical Research Center, whereas patients 5 and 6 and
the six normal controls were studied as outpatients. The normal
controls had no history of renal abnormalities. Glomerular filtra-
tion rate (GFR) was calculated by measuring the urinary clear-
ance of '251-iothalamate following a dose of saturated potassium
iodide and a standard water load [26]. Approximately one hour
after subcutaneous injection of 35 iCi of '251-iothalamate, blood
and urine samples were taken at 30 minute intervals for four
periods. Patient 4 was studied for only two time periods because
of weakness. At the end of the third period (second period for
patient 4), venous blood was obtained to measure glucose,
bicarbonate, phosphorous, plasma amino acids, and serum or-
ganic acids. Phosphorous, glucose, amino acids, and organic acids
were also measured in urine collected during this period. Amino
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Table 2. Summary of OXPHOS biochemistry and mtDNA genetic analyses
Mean Mean
1 2 3 4 5 6 (5% level) (5% level)
(23 years) (44 years) (47 years) (61 years) (43 years) (55 years) <50 years >50 years
Complex I NADH-DB 34 2P 207 ND ND 76 144 45 67 34
Complex NADH-Cyt c
1+111
43 ii5 294 ND ND 26 (64) (14)301 98 90 53
(129) (13)
Complex Succinate- 610 410 1099 ND ND 269 568 141 245 898
11+111 Cyt c (306) (200)
Complex DBH2-Cyt c 1203 1091 2668 ND ND 1457 1554 387 1339 347
III (838) (735)
Complex Cytochrome c 610 751 ND ND ND 420 1371 381 1097 285
IV (FT) oxidase (676) (584)
(FF)
Complex
IV (SON)
Cytochrome c 139 69 944 ND ND 708 1857 366 1480 268
oxidase (1157) (992)
(SON)
MtDNA mutation MTIFK* M1ITK* MTFK5 MTTK* 5 kb Unknown
(tissue analyzed) MERRF8344G
(skeletal
muscle)
MERRF84344G
(skeletal
muscle)
MERRF8344G
(skeletal
muscle)
MERRF8344G
(skeletal
muscle)
deletion
(skeletal
muscle)
mutation
(skeletal
muscle)
NADH-DB, NADH-n-decyl coenzyme Q oxidoreductase; NADH-Cyt c, NADH cytochrome c oxidoreductase (rotenone sensitive fraction);
succinate-Cyt c, succinate-cytochrome c oxidoreductase; DBH2-Cyt c, reduced n-decyl coenzyme Q-cytochrome c oxidoreductase; FT. freeze thaw
disruption of mitochondria; SON, disruption of mitochondriàl with 6 seconds of sonication ND, analysis not done. Enzyme activity is reported in
nanomoles of substrate/minute/mg mitochondrial protein. <50 years signifies 20 controls who are distributed within the age range 18 to 49 years; >50
years is 19 controls who are distributed within the age range 50 to 78 years. The mean specific activities and the standard deviations for each assay are
given. The 5% tolerance level of the control group is in parenthesis.
aValues are below the 5% tolerance limit for normal adults
acids and organic acids were quantified using a Beckman 6300
amino acid analyzer and a Hewlett Packard 5790 Gas Chromato-
graph, respectively [27, 28]. The fractional excretion (FE) was
calculated for phosphorous, glucose, and amino acids with the
following equation to correct for differences in GFR.
[(Urine concentration X Urine flow rate)! (Serum concentration
x GFR)] x 100
Statistical analyses
The 5% and 95% tolerance levels for the OXPHOS enzyme
specific activities, the GFR, the FEphosphate, FEiactate, FEurate,
FEgiocose, and FEamino acids were calculated for the control data
sets [29]. The tolerance levels for each data set were corrected for
sample size [29]. GFR and OXPHOS enzyme specific activities
were considered abnormal if they were below the control 5%
tolerance level. The fractional excretion for a compound was
considered abnormal if the value was above the 95% tolerance
level.
Results
Genetic and biochemical evaluation of OXPHOS
All six patients had defects in OXPHOS function based on
biochemical and/or genetic criteria. The OXPHOS biochemistry
analyses for individuals 1 to 3 were previously reported [11].
Prominent biochemical defects in OXPHOS were identified in
patients 1, 2, 3, and 6. The OXPHOS assays for Complexes I and
IV were abnormal in patients 1 and 2, whereas only the Complex
IV assay was abnormal in patients 3 and 6 (Table 2).
Patients 1 to 4 harbored the MTTK*MERFF8344G mutation
[11, 12]. This A to G mutation is located in the TtpC loop of the
tRNAYs gene and produces a significant impairment in mito-
chondrial protein synthesis when high levels are present within
cells [30]. Patient 5 had a 5 kb deletion in mtDNA isolated from
a skeletal muscle biopsy and harbored approximately 50% mutant
and 50% normal mtDNAs. Direct sequencing across the deletion
breakpoint of the mutant mtDNA showed that 4977 nucleotide
pairs were deleted between np 8469 of the ATPase 6 gene and np
13,446 of the ND5 gene, removing a portion of these two genes as
well as the complete genes coding for tRNALte, tRNASCImC,
tRNAttke, tRNAy0e, and the ND4, ND4L,
ND3, and COIlI subunits. Although a large number of different
deletions have been reported in this region of the mtDNA, this 5
kb deletion is observed in about 50% of the patients with this
disorder [31, 32].
Skeletal muscle mtDNA from patient 6 was tested for known
mtDNA mutations by Southern blot and by point mutation
analyses. No mtDNA deletions and duplications were observed on
Southern blot using BamFil and EcoRV restriction endonucleases
to cut the mtDNA. The MTATP6*NARP8993G, MTATP6*
NARP8993C, MTFK*MERRF8356C, M1TI'K*MERRF8344G,
MYrL1*MELAS3271C, MTTL1*MMC326OG, M1TL1*MM3250C,
and MTTL1 *MELAS3243G mutations were not present in skel-
etal muscle mtDNA. Although the precise mtDNA mutation
responsible for this patient's phenotype is unknown at this time,
the abnormal muscle pathology and the respiratory chain defects
identified in skeletal muscle mitochondria confirmed that he had
an OXPHOS disease.
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Table 3. GFR and indices of proximal tubular function in patients with
OXPHOS diseases
Control
X±SD 5%—95% 1 2 3 4 5 6
GFR mI/mm 118.8 12.9 83.0—154.6 89 83 83 72 85 100
Fractional
excretion %
Phosphate
Lactate
Urate
Glucose
5% to 95% tolerance limits are calculated as the control mean (k)SD,
where the tolerance factor (k) for N = 6 is 2.7766.
Metaholites with an FE above the 95% tolerance limit
Analysis of proximal renal tubule function
Although the GFR of each of the six patients was below the
mean value of the six control subjects (Table 3), all patients except
for patient 4 had GFR values within the 5% to 95% tolerance
limits. No patient had abnormalities in the urine such as protein-
uria, hematuria, or cylinduria (casts) to suggest underlying kidney
disease. To take into account the variability in renal function, we
calculated the fractional excretion of specific sodium-coupled
reabsorption processes in patients and controls (Table 3). The
FEphosphate was normal in all six patients. Abnormalities in the
FEgcosc, FEurate, and FEiactate were present only in the individ-
uals who harbored the MTTK*MERRF8344G mutation. The
FEgiuct,se was increased in patient 1 who had MERRF and FEurate
was increased in her maternal aunt (patient 3). The FEjactate for
patient 1 and her mother (patient 2) was above the 95% tolerance
limit of the controls with values of 1.7% and 0.4%, respectively.
The other four individuals (patients 3 to 6) had a FEiactate of 0%.
This observation is consistent with the fact that many patients who
harbor OXPHOS defects have normal plasma and urine lactate
levels.
A generalized aminoaciduria was the most frequently encoun-
tered abnormality in these patients (Table 4). This proximal
tubule abnormality was identified in three of the patients who
harbored the MTTK*MERRF8344G mutation (patients 1, 3, and
4) and in the individual with a mitochondrial myopathy (patient
6). The most significant increases in the fractional excretion of
amino acids were observed for neutral amino acids. The fractional
excretions of acidic and basic amino acids were normal. The
significance of the isolated increase in the in patient 2
who harbored the MTTK*MERRF8344 mutation and
FEmethjonine in patient 5 who harbored a 5 kb mtDNA deletion is
unclear.
Discussion
Approximately 95% of oxygen delivered to tissues is used by
OXPHOS for ATP production. The heart has the highest oxygen
consumption per gram of tissue, followed by kidney, brain, liver,
and skeletal muscle, reflecting the dependence of these organs on
OXPHOS for normal function [33]. Although cellular energy
requirements are important in determining which organs will be
affected most severely, clinical manifestations of OXPHOS dis-
eases are also influenced by the capacity of the organ to compen-
sate for cellular dysfunction. Hence, these patients commonly
have neurological manifestations, reflecting the high ATP re-
12.9 5.8 0—29.0 15.6 15.5 24.1 11.0 24.4 2.8
0.04 0.09 0—0.29 1.T' 0.4 0 0 0 0
10.8 3.9 0—21.6 — 9.1 24.0' 4.1 17.3 10.6
0 0 0.9e 0 0 0 0 0
quirements as well as the limited ability of neurons to compensate
for cell loss. OXPHOS abnormalities in heart, type I skeletal
muscle, and endocrine organs such as the pancreas are associated
with a wide range of manifestations that include cardiomyopa-
thies, arrhythmias, myopathies, and diabetes mellitus. Generally,
liver and kidney exhibit minor clinical abnormalities, possibly
reflecting the fact that these organs can undergo significant
cellular degeneration before symptoms appear [1, 341.
Roughly 80% to 90% of the oxyen consumed by the kidney is
used for sodium coupled transport processes linked to sodium-
potassium-ATPase (Na-K-ATPase) [35—37]. Na-K-ATPase
activity is highest in the proximal tubule, the thick ascending limb
of Henle's loop, and the distal convoluted tubule. Ultrastructural
examination shows these regions have large numbers of mitochon-
dna [381. Since the proximal tubule reabsorbs approximately 99%
of filtered glucose, phosphate, and amino acids by specific sodium
coupled transporters and this process is ATP dependent,
OXPHOS dysfunction could impair the activity of sodium-cou-
pled transport processes. In fact, prior to the recognition of
mtDNA mutations as a cause of OXPHOS diseases, an abnor-
mality in OXPHOS was proposed as one of several possible
causes for the proximal renal tubule dysfunction observed in the
Toni-Fanconi-Debré syndrome [391.
The importance of normal OXPHOS function in sustaining
sodium-coupled transport processes is supported by the types of
renal abnormalities observed in infants and children with
OXPHOS diseases. In OXPHOS disorders caused by mtDNA
deletions, affected infants can manifest generalized aminoacid-
uria, Bartter syndrome [71, or renal tubular acidosis [6]. A distinct
group of patients with an OXPHOS disease called lethal infantile
mitochondrial disease is characterized by failure to thrive, weak-
ness, hypotonia, severe lactic acidosis, and death within the first
year of life [1]. The renal tubular abnormalities include general-
ized aminoacidurias [40—43] and the De Toni-Fanconi-Debré
syndrome [2, 44]. Although there is biochemical and genetic
heterogeneity in this group of patients, accounting for the vari-
ability in the severity of tissue involvement [34], some patients
with lethal infantile mitochondrial myopathy have tissue-specific
depletions of the mtDNA [45—491. In these infants, mtDNA copy
number is severely reduced in affected tissues and correlates with
the abnormalities identified in Complex IV histochemistry and
immunohistochemistry. Hence, tissues with extremely low quan-
tities of mtDNA are unable to synthesize the mitochondria-
encoded subunits necessary to sustain adequate OXPHOS func-
tion. Although renal manifestations occur in infants and children
with OXPHOS diseases, the severe, systemic manifestations en-
countered in these patients can make the assessment of renal
tubule function difficult to perform and interpret.
By contrast, the sytemic effects of an OXPHOS defect in adults
are generally less severe and clinically significant renal dysfunc-
tion is unusual, thus permitting a more detailed characterization
of renal function. In our analysis of adult patients with OXPHOS
diseases, abnormal proximal renal tubule amino acid reabsorption
was the most frequently identified abnormality and was charac-
terized by increased FE of neutral amino acids. These defects
were present in four of the six patients investigated. The impaired
reabsorption of neutral amino acids in these patients included
aliphatic amino acids (alanine, glycine, leucine, and isoleucine),
hydroxy-containing aliphatics (serine and threonine), an aromatic
amino acid (tyrosine), an w-amide amino acid (glutamine), and
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Table 4. Fractional excretion of amino acids by normal adults and patients with OXPHOS diseases
ControlX so Controlrange
Control
5%—95% 1 2 3 4 5 6
Acidic amino acid
Glutamic acid 0.46 0.57 0—1.45 0—2.04 0 0.10 0.44 0.59 0 0
Basic amino acids
Lysine 0.69 0.60 0.12—1.79 0—2.36 0.96 0.21 0.80 0.27 0.24 1.65
Ornithine 0.52 0.13 0.33—0.68 0.16—0.88 0.53 0.76 0.64 0,64 0.38 0.32
Arginine 0.15 0.08 0—0.25 0—0.37 0.13 0 0 0 0.21 0
Neutral amino acids
Simple aliphatic
Alanine 0.30 0.04 0.24—0.36 0.19—0.41 0.95a 0.38 0.50a 0.41a 0.39 0.66a
Glycine 3.84 1.38 2.41—5.26 0—7.67 18.34a 2.70 6.64 2.46 3.42 5.04
Isoleucine 0.22 0.10 0.09—0.35 0—0.50 0.54a 0.20 0.13 0.30 0.34 0.15
Leucine 0.29 0.09 0.16—0.41 0.04—0.54 0.40 0.30 0.35 0.58a 0.15 0.34
Valine 0.26 0.05 0.21—0.36 0.12—0.40 0.28 0.22 0.25 0.21 0.25 0.22
1-lydroxy-containing aliphatic
Threonine 0.61 0.09 0.51—0.72 0.36—0.86 1.34 0.58 1.06a 0.86a 0.82 1.02a
Serine 1.65 0.24 1.31—1.91 0.98—2.32 3.76 2.13 1.68 2.89a 2.02 2.55a
w-Amides
Glutamine 0.44 0.09 0.31—0.52 0.19—0.69 0.51 0.36 3.17a 0.46 0.42 Ø73a
Sulfur containing
Methionine 0.79 0.34 0.53—1.45 0—1.73 1.30 0.80 1.31 1.78a 5.02a 0.80
Cystine 0.63 0.17 0.45—0.90 0.16—1.10 2.51a lisa 0.95 0.65 0.56 1.16
Aromatic
Phenylalanine 1.98 3.52 0.38—9.16 0—11.75 2.32 0.62 0.81 0.59 0.61 0.64
Tyrosine 1.20 0.37 0.64—1.70 0.17—2.23 2.47a 1.78 3.46a 3.12a 1.96 2.25a
Heterocyclic
Histidine 5.12 1.91 3.26—7.19 0—10.42 10.38 3.75 8.36 0.32 6.64 9.61
Neutral amino acids have no net charge at physiological pH, whereas the acidic and basic amino acids have negative and positive charges, respectively.
The classification of amino acids is according to Silbernagl (1988) [50]. 5% to 95% tolerance limits are calculated as mean (k)sD, where the tolerance
factor (k) for N = 6 is 2.7766.
a Amino acids with an FE that is above the 95% tolerance limit
sulfur containing amino acids (methionine and cystine). The
proximal renal tubule reabsorption of these amino acids involves
a variety of sodium dependent amino acid transporters that are
linked to Na-K-ATPase activity [501.
Two considerations are important when evaluating proximal
tubule function. First, fractional excretion measurements may not
detect subtle renal OXPHOS defects due to the sensitivity of this
type of analysis and due to the complex nature of tubular
reabsorption processes for phosphate, lactate, glucose, and amino
acids (such as, the renal Tm for glucose). Second, the calulation of
fractional excretion values to detect OXPHOS defects would not
be appropriate in patients with advanced renal insufficiency.
Nadvornikova et al studied 5 patients with inulin clearances in the
5 to 10 ml/min range and found a generalized increase in the
fractional excretions of all amino acids [51]. From the average
values of urinaly amino acid excretions of five patients with inulin
clearances from 10 to 32 ml/min published by Tizianello et al, it
can be estimated that chronic renal failure increases the fractional
excretions of virtually all amino acids [52]. However, the same
generalized increase may not be found in patients with less severe
renal insufficiency. Gulyassy et al studied five patients with "mild
chronic renal disease" and creatinine clearances from 26 to 69
ml/min and calculated the fractional excretions of amino acids
using creatinine clearances for GFR [53]. FEGlycifle, FEHistidine,
FEpartate, FEMethionine, and FEGlutamate were below values in
normal subjects while FETyrosine, FEOFflIthIfl, FEi'hreonine,
FEiutamine, and FEAlanine were not significantly different from
normal values. Thus, our results support the conclusion that
OXPHOS dysfunction can cause generalized aminoaciduria in
adults because the reduced ATP production by proximal tubule
cells limits Na-K-ATPase activity which impairs sodium-cou-
pled transport processes.
An important observation was that patients 2 and 3 had mild
clinical manifestations of OXPHOS dysfunction. Confirmation of
the presence of a mitochondrial myopathy required performing
detailed muscle pathology and OXPHOS biochemistry on skeletal
muscle. The mild clinical defects, hearing loss, and fatigability
were accompanied by an increase in amino acid clearances
suggesting that proximal renal tubule dysfunction may be an
important clue to an underlying OXPHOS disease. If common
causes of proximal tubule dysfunction are excluded in a patient
with a generalized aminoaciduria, OXPHOS diseases should be
considered in the differential diagnosis and if a pathogenic
mtDNA mutation is identified, genetic counseling is warranted.
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